HAI-1 [HGF (hepatocyte growth factor) activator inhibitor-1] is a Kunitz-type transmembrane serine protease inhibitor that forms inhibitor complexes with the trypsin-like serine protease, matriptase. HAI-1 is essential for mouse placental development and embryo survival and together with matriptase it is a key regulator of carcinogenesis. HAI-1 is expressed in polarized epithelial cells, which have the plasma membrane divided by tight junctions into an apical and a basolateral domain. In the present study we show that HAI-1 at steady-state is mainly located on the basolateral membrane of both Madin-Darby canine kidney cells and mammary gland epithelial cells. After biosynthesis, HAI-1 is exocytosed mainly to the basolateral plasma membrane from where 15 % of the HAI-1 molecules are proteolytically cleaved and released into the basolateral medium. The remaining membrane-associated HAI-1 is endocytosed and then recycles between the basolateral plasma membrane and endosomes for hours until it is transcytosed to the apical plasma membrane. Minor amounts of HAI-1 present at the apical plasma membrane are proteolytically cleaved and released into the apical medium. Full-length membrane-bound HAI-1 has a half-life of 1.5 h and is eventually degraded in the lysosomes, whereas proteolytically released HAI-1 is more stable. HAI-1 is co-localized with its cognate protease, matriptase, at the basolateral plasma membrane. We suggest that HAI-1, in addition to its protease inhibitory function, plays a role in transporting matriptase as a matriptase-HAI-1 complex from the basolateral plama membrane to the apical plasma membrane, as matriptase is known to interact with prostasin, located at the apical plasma membrane.
INTRODUCTION
It is becoming increasingly clear that extracellular proteases and protease inhibitors play an important role in cellular migration and differentiation during normal development. In most cases genetic ablation of the protease inhibitor has no effect, suggesting an extensive developmental redundancy. However, the protease inhibitor HAI-1 [HGF (hepatocyte growth factor) activator inhibitor-1] has been shown to be essential during embryonic development, as HAI-1-deficient mouse embryos die during midgestation [1] . HAI-1 is an inhibitor of several serine proteases including matriptase. Matriptase-deficient mice die shortly after birth [2] . Mice deficient in both HAI-1 and matriptase develop to term and are born with the same phenotype as a matriptasedeficient mouse [3] . This shows that HAI-1 is an essential nonredundant inhibitor of matriptase during prenatal development. In addition, recent studies in zebrafish have shown that matriptase and HAI-1 regulate skin homoeostasis and remodelling [4] . In the present study it was shown that an insertion in the HAI-1 gene caused an accumulation of neutrophils in the fin which could be rescued by knockdown of matriptase, suggesting that HAI-1 and matriptase also play a role in regulating inflammation. The protease-protease inhibitor pair, matriptase and HAI-1, has also been shown to play an important role in carcinogenesis. Modest overexpression of matriptase in the skin of transgenic mice caused spontaneous squamous cell carcinoma, accompanied by dramatically potentiated carcinogen-induced tumour formation. Simultaneous overexpression of HAI-1, however, completely negated the oncogenic effects of matriptase overexpression [5] .
HAI-1 is a Kunitz-type serine protease inhibitor and was first identified as an inhibitor of HGF activator, a blood coagulation Factor XII-like serine protease [6] . It has later been shown to also inhibit matriptase [7] , prostasin [8] and hepsin [9] . Full-length HAI-1 is composed of 513 amino acids and consists of two welldefined extracellular Kunitz domains, KD1 (residues 246-306) and KD2 (residues 371-431), an LDLR (low-density lipoprotein receptor-like domain) class A domain (residues 315-360), a transmembrane domain and a short C-terminal cytoplasmic domain [6] . HAI-1 is expressed in most epithelial cells including kidney, placenta, pancreas, prostate, intestine and lung [6, 10] .
Matriptase is a type II transmembrane serine protease that is expressed in many epithelial cells and some haematopoietic cells [11] [12] [13] . Matriptase activates the serine proteases, prostasin [14] and uPA (urokinase-type plasminogen activator) [15, 16] , as well as non-protease substrates such as protease-activated receptor 2 [15] and HGF [16] via proteolytic cleavage.
Epithelial cells form a tight monolayer of cells that line the internal surfaces of our organs and the external surfaces of our bodies. Many of these are specialized for absorption and secretion. The entire organization of the epithelium is polarized, which is most easily observed at the plasma membrane, as this is divided into an apical and a basolateral membrane. The plasma membrane is divided by tight junctions between neighbouring cells into two membrane domains; the apical membrane domain and the basolateral membrane domain [17] . The functions of the two membrane domains are distinct, and their lipid and protein composition are strikingly different. The tight junctions prevent the mixing of outer-leaflet proteins and lipids between the two surfaces, and also act as a selective barrier between adjacent cells to prevent large molecules from crossing the epithelial layer [18, 19] .
As described above, the activity of matriptase is tightly regulated by its interaction with HAI-1. However, matriptase and HAI-1 are expressed in the same cells. In order to gain an understanding of the time and place for the molecular interaction between them it is necessary to map the intracellular itinerary of these molecules as well as their molecular interactions. In the present study we have investigated the subcellular itinerary of HAI-1 in the natural environment for these molecules, a polarized epithelial cell. The results of the present study show that matriptase and HAI-1 are co-localized at the basolateral plasma membrane and that HAI-1 has a complex subcellular itinerary, including transcytosis from the basolateral to the apical plasma membrane.
EXPERIMENTAL
Cell culture and DNA constructions MDCK (Madin-Darby canine kidney) cells were grown in minimal essential medium supplemented with 2 mM L-glutamine, 10 % fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin (Gibco) at 37
• C in an atmosphere of 5 % CO 2 . Cells were transfected with the eukaryote expression plasmid pMH containing the cDNA encoding full-length murine HAI-1 or encoding the full-length murine matriptase (epithin) cDNA. Subconfluent MDCK cells were transfected by the calcium phosphate transfection procedure as described previously [20] . The transfected cells were selected using 0.65 mg/ml G418, and stable clones were isolated using cloning cylinders. For most experiments, 10 6 cells per well were seeded into 24-mm Transwell chambers (Costar), allowing separate access to the apical and basolateral membrane. The medium was changed every 2 or 3 days. Filters were used for experiments 3-6 days after confluence as indicated by tightness of the filters. The tightness of filter-grown cells was assayed by filling the inner chamber to the brim and allowing it to equilibrate overnight.
Immunofluorescence
MDCK cells expressing HAI-1 grown on coverslips or on filters or mammary gland cryosections were fixed in 4 % (w/v) paraformaldehyde in PBS. Unspecific staining was blocked with PBS, 1 mM MgCl 2 and 0.1 mM CaCl 2 (PBS ++ ) containing 3 % BSA for 20 min at room temperature (22 • C). In some cases, cells were immunostained before permeabilization in the following manner: cells were incubated with primary antibody diluted in PBS ++ containing 3 % BSA (PBS/BSA) for 1 h at room temperature, rinsed three times with PBS/BSA followed by incubation with relevant Alexa Fluor ® -conjugated secondary antibodies (Invitrogen; 1:300) for 45 min at room temperature. Where indicated, cells were permeabilized with PBS/BSA containing 0.1 % Triton X-100 for 20 min. Labelling of intracellular antigens was performed as described for surface staining except 0.1 % Triton X-100 was included in all buffers. If indicated, sections were subsequently incubated with streptavidin-conjugated Alexa Fluor ® 594 (Invitrogen) diluted 1:300 and finally mounted with DAPI (4 ,6-diamidino-2-phenylindole) vectashield hard set mounting medium (VWR) and subjected to laser scanning confocal microscopy using the Leica TCS SP2 system.
Where indicated, cells were treated with 200 nM bafilomycin (Sigma-Aldrich) for 24 h before fixation. Primary antibodies employed were: goat anti-mouse HAI-1 antibody (catalogue number AF1141, R&D systems) diluted 1:8000 and rabbit antimatriptase antibody (catalogue number IM1014, Calbiochem) diluted 1:1000.
Immunoblotting
NuPAGE gels (10 %) were used according to the manufacturer's protocol (Invitrogen) and were semi-dry blotted on to Immobilon-P PVDF membranes (Millipore). The blots were blocked with 2 % (v/v) Tween 20 in PBS, probed with an anti-HAI-1 antibody (1:1000), and then probed with an appropriate secondary antibody. The signal was developed using an ECL ® (enhanced chemiluminescence) substrate reagent according to the manufacturer's protocol (Amersham Pharmacia Biotech) and was developed with a Fuji LAS1000-camera (FujiFilm Sverige AB).
RT (reverse transcriptase)-PCR
Total RNA was purified from MDCK cells as recommended by the manufacturers using the E.Z.N.A. total RNA kit II (VWR). RNA purification included a DNase treatment. The cDNA synthesis was performed on approx. 150 ng of RNA per 20 μl using high-capacity cDNA archive kit (Applied Biosystems). Quantitative Power SYBR Green PCR master mix (Applied Biosystems) was used together with 900 nM of each primer. Primers were designed using Primer Express v3.0 Software and placed within different exons. Quantitative RT-PCR was performed on the ABI 7300 sequence detection system (Applied Biosystems). Primers were obtained from TAC (Copenhagen). Canine matriptase primers were matriptase F (forward), 5 -TGGC-TTGCCTCCTGATGTG-3 and matriptase R (reverse), 5 -TGA-TCCTCAGGTAGCCATTGAA-3 . Canine HAI-1 primers were HAI-1 F (forward), 5 -TTTGAGGAGGAGCAGCAGTGT-3 and HAI-1 R (reverse), 5 -GCCGCAGGCCGAAAAC-3 . Canine β-actin primers were β-actin F (forward), 5 -CGACAGGATG-CAGAAGGAAATC-3 and β-actin R (reverse), 5 -CGTTCC-GGAGGAGCAATG-3 . Negative controls (where the RNA was not converted into cDNA) and positive controls were included.
Metabolic labelling, biotinylation, immunoprecipitations and streptavidin precipitations
Metabolic labelling was performed on tight filter-grown cells using 0.25 mCi of [ 35 S]methionine in 1 ml per well as described previously [20] . Biotinylation and stripping of biotin using glutathione was performed essentially as described in [21, 22] . Cells were washed three time in PBS and biotinylated with 1 mg/ml s-NHS-SS-biotin [sulfosuccinimidyl-2-(biotinamido)-ethyl-1,3-dithiopropionate] in the same buffer at 4
• C for 30 min. The reaction was quenched by washing the cells three times in PBS, by a 5 min incubation with 50 mM glycine in PBS, and by another three washes with PBS. The cells were then incubated in medium (described above) for the indicated time at either 4
• C or 37 • C. If indicated, cell-surface biotin was stripped with two 20 min incubations with 50 mM reduced glutathione, 75 mM NaCl, 75 mM NaOH and 1 mM EDTA with 1 % BSA. Cells were subsequently rinsed twice with PBS and incubated for 5 min with 5 mg/ml iodoacetamide in PBS to quench any residual glutathione. After two additional rinses with PBS, cells were either extracted for Western blot analysis or prepared for immunoprecipitation. For immunoprecipitation, the cells were lysed in PBS containing 1 % Triton X-100, 5 mM EDTA and 0.5 % deoxycholate for 30 min at 4
• C and the apical and basolateral media were collected. The extracts were centrifuged (5000 g for 2 min), and the supernatant was recovered and incubated for 60 min with 100 μl of a 50% Protein A-Sepharose slurry and incubated for 2 h at 4 • C. The supernatant was recovered after centrifugation (5000 g for 2 min) and 100 μl of HAI-1 antibody (diluted 1:100) and 20 μl of 50% Protein A-Sepharose slurry were added. The sample was rotated end-over-end for 2.5 h at 4
• C. The immunoprecipitates were washed five times in 50 mM Tris/HCl (pH 8.0), 1.0 % (v/v) Nonidet P40 and 500 mM NaCl. The immunoprecipitates were in some cases analysed by electrophoresis on SDS/PAGE (10 % gels). The gels were dried, exposed to X-ray films and processed for densitometry or analysed on a phosphorimager (Molecular Dynamics PhosphorImager SITM). Alternatively, for streptavidin precipitation the immunoprecipitate was boiled in 80 μl of SDS/PAGE sample buffer without dithiothreitol and diluted in 1 ml of 25 mM Tris/HCl (pH 7.8), 250 mM NaCl, 5 mM EDTA, 1 % (v/v) Triton X-100, 1 % BSA and 10 % fetal bovine serum and centrifuged at 3000 g for 5 min. The supernatant was then incubated with streptavidin agarose (50 μl of a 50% slurry) at 4
• C overnight. The streptavidin beads were washed four times with 25 mM Tris/ HCl (pH 7.8), 500 mM NaCl and 0.5 % Triton X-100 and then three times in 10 mM Tris/HCl (pH 7.8) and 150 mM NaCl. The streptavidin precipitate was analysed on SDS/PAGE (10 % gels). The gels were dried and analysed on a phosphorimager.
RESULTS

HAI-1 can be recombinantly expressed in MDCK cells
The cDNA coding for the full-length wild-type murine HAI-1 was incorporated into the eukaryotic expression vector pMH and transfected into MDCK cells. Twenty-four G418-resistant clones were isolated and the majority of the clones showed HAI-1 expression as tested by immunocytochemistry (results not shown). All clones showed a similar pattern of expression characteristic of basolaterally expressed proteins, e.g. along the cell periphery. One clone (clone 21) was selected for further investigation based on the intensity of the immunocytochemistry reactions. No immunostaining could be detected in non-transfected cells or in transfected cells when the primary antibody was omitted. A cell extract of clone 21 was analysed by Western blotting using conventional SDS/PAGE and showed an HAI-1 immunoreactive band of 52 kDa under non-reducing conditions, whereas no immunoreactive band could be detected in non-transfected MDCK cells (Figure 1 ). Bands of equal intensity could be identified after stripping of the blots and reprobing with an antibody against the transferrin receptor, indicating that equal amounts of sample were loaded in the two wells. Our findings correspond well with the molecular mass of HAI-1 found in previous studies (55-66 kDa) [23, 24] .
MDCK cells have an endogenous expression of HAI-1 and matriptase
In order to investigate whether MDCK cells have an endogenous expression of the canine matriptase and HAI-1 mRNAs, we used quantitative real-time RT-PCR and normalized to the expression of canine β-actin mRNA. Total RNA was extracted from MDCK cells and was, after cDNA synthesis, used as a template in a quantitative real-time PCR reaction. The mRNA levels of matriptase and HAI-1 relative to the expression of canine β-actin were 0.11 and 0.06 respectively. No signal could be detected when RT was omitted. Analysis of the melting curves and analysis of the products on agarose gels showed that there was only a single In order to evaluate the steady-state distribution of exogenously expressed HAI-1 in MDCK cells, we analysed the distribution of HAI-1 between intracellular and extracellular compartments of the cell. Clone 21 cells were grown on coverslips, fixed and thereafter surface HAI-1 (termed HAI-1 surface hereafter) was visualized by immunofluorescence in the absence of detergent (Figures 2a and 2d) . Next, cells were permeabilized and HAI-1 was detected again using the same primary antibody but a different secondary antibody to indicate the localization of both intracellular and extracellular HAI-1 (termed HAI-1 total hereafter) (Figures 2b and 2e ). Confocal microscopy of cells stained in this manner revealed that the majority of HAI-1 total co-localized with HAI-1 surface and only a minor fraction of HAI-1 total was not co-localized with HAI-1 surface . The intracellular material represents newly synthesized molecules on their way to the plasma membrane, but may also include material that, after endocytosis, is undergoing transport to other cellular destinations.
To evaluate the distribution of HAI-1 between the apical and the basolateral plasma membrane, clone 21 cells were grown on filters until confluence, biotinylated on either the apical (Figures 2g-2i) or the basolateral (Figures 2j-2l ) plasma membrane and thereafter processed for immunofluorescence. The cells were labelled for surface HAI-1 (Figures 2h and 2k) , whereas biotinylated proteins were visualized using Alexa Fluor ® 594-labelled streptavidin (Figures 2g and 2j) . We found that the vast majority of HAI-1 co-localized with proteins biotinylated from the basolateral side but occasionally faint staining for HAI-I in scattered dots could be MDCK cells expressing HAI-1 were labelled for HAI-1 in the absence of detergent to detect HAI-1 at the plasma membrane (HAI-1 surface ; a and d); thereafter labelling for HAI-1 was repeated using the same primary antibody but a different secondary antibody in the presence of detergent to detect both intracellular and extracellular HAI-1 (HAI-1 total ; b and e). An overlay of (a) and (b) is shown in (c), and an overlay of (d) and (e) is shown in (f). Tight filter-grown MDCK cells were biotinylated from either the apical side (g) or the basolateral side (j) and thereafter labelled for HAI-1 (h and k). An overlay of (g) and (h) is shown in (i) and an overlay of (j) and (k) is shown in (l). HAI-1 is mainly located on the basolateral membrane in the mouse mammary gland. Mouse mammary gland from mouse at the tenth day of lactation was labelled for HAI-1 and analysed by confocal microscopy (m). MDCK cells expressing HAI-1 were transiently transfected with an expression vector coding for matriptase. Cells were labelled for HAI-1 (n) and matriptase (o). An overlay of (n) and (o) is shown in (p).
detected on the apical plasma membrane. In order to verify that the basolateral localization of HAI-1 in MDCK cells reflected a physiological situation we next investigated the subcellular localization of HAI-1 in mammary epithelial cells. Mammary epithelial tissue was taken from a mouse at the tenth day of lactation. Paraformaldehyde-fixed cryosections were labelled with anti-HAI-1 antibodies in the presence of detergents and analysed by confocal microscopy. A clear basolateral localization of HAI-1 was observed (Figure 2m) . Similar results were obtained with mouse mammary glands at the time of birth and at the second day of involution (results not shown).
HAI-1 is a physiologically important inhibitor of matriptase and the two proteins have been purified as a complex, showing that they interact directly [7] . To investigate in which subcellular compartments matriptase and HAI-1 co-localize, clone 21 cells were transiently transfected with an expression vector coding for full-length murine matriptase and seeded on to coverslips. The transfected cells were double-labelled with antibodies directed against HAI-1 ( Figure 2n ) and matriptase (Figure 2o ) and the localization of the two proteins was analysed by confocal microscopy. The matriptase antibody did not detect the canine matriptase endogenously expressed in MDCK cells as no labelling could be detected in non-transfected clone 21 cells (results not shown). However, we could detect clone 21 cells transiently expressing matriptase co-localizing with HAI-1 on the basolateral plasma membrane (Figure 2p ).
HAI-1 is exocytosed primarily to the basolateral plasma membrane
To study the appearance of newly synthesized proteins on the two cell-surface domains, tight filter-grown cells were pulse-labelled with [ 35 S]methionine for 10 min, and after various chase times the plasma membrane proteins present on either the apical or basolateral domains were biotinylated using a membrane nonpermeant biotinylation reagent. Biotinylated HAI-1 was purified by immunoprecipitation using Protein A-Sepharose, released from the beads by boiling and reprecipitated with streptavidinagarose. The resulting purified antigens were analysed on NuPAGE gels, and quantified on a phosphorimager. The analysis showed that newly synthesised HAI-1 appears as a clear transient pool on the basolateral plasma membrane, peaking at 1 h of chase ( Figure 3) . A smaller transient pool can be seen on the apical plasma membrane, displaying a broad peak at 0.5-2 h of chase. These results show that the majority of HAI-1 is initially exocytosed to the basolateral plasma membrane. After short chase times minor amounts of HAI-1 appeared at the apical and the basolateral plasma membrane with the same kinetics. It can thus not be excluded that minor amounts of HAI-1 are transported directly from the Golgi apparatus to the apical plasma membrane.
A fraction of HAI-1 is secreted to the basolateral side of MDCK cells whereas the majority remains cell-associated
To investigate whether the HAI-1 ectodomain is released to the apical or basolateral sides, clone 21 cells were grown to confluence on transwells, biosynthetically labelled with [ 35 S]methionine for 10 min and chased for the times indicated (Figure 4) . The apical medium, the basolateral medium and the cell extracts were collected at various time points. HAI-1 was immunoprecipitated and analysed on NuPAGE gels and quantified using a phosphorimager. A band of 52 kDa presumably representing full-length membrane-bound HAI-1 could be seen in the cell extracts after short chase times. This membrane-bound form has a relatively short half-life of 1.5 h. At later time points immunoreactive bands, which appear to have a precursor product relationship with the 52 kDa band, appeared in the cell extract suggesting that the 52 kDa band was successively degraded. After 2 h of chase, approx. 15 % of the HAI-1 immunoreactive species can be detected in the basolateral medium and 2 % in the apical medium. These fractions were relatively stable and are still present after 5 h of chase. These results showed that, in MDCK cells, minor amounts of HAI-1 were proteolytically released into the medium.
Plasma-membrane-associated HAI-1 is rapidly endocytosed
In order to investigate whether HAI-1 on the plasma membrane is endocytosed, clone 21 cells were grown on plastic to subconfluence, and proteins on the plama membrane were biotinylated using a cleavable biotinylation reagent, s-NHS-SS-biotin. The cells were then allowed to endocytose for the time indicated at either 4
• C or 37 • C. Thereafter, surface-exposed biotin was stripped using a membrane non-permeant reducing agent, glutathione. The cells were extracted and streptavidin precipitated, and thereafter analysed by Western blotting using an HAI-1 antibody. The Western blot was quantified using an image gauge. When the cells were biotinylated at 4
• C and immediately stripped, only a minor background of biotinylated HAI-1 could be detected, showing that the stripping procedure is efficient ( Figure 5) . Significantly higher signals could be detected when cells were allowed to endocytose at 37
• C for 5, 10 or 15 min before stripping, showing that some HAI-1 molecules have now acquired protection from the non-membrane-permeant reduction procedure. Maximal signal was detected when the cells were allowed to endocytose for 10 min. After 15 min of chase the signal was reduced, possibly due to recycling or degradation of HAI-1. The maximal signals after 10 min were approx. 75 % of the total surface-biotinylated HAI-1 ( Figure 5 ). These results show that HAI-1 at the plasma membrane is rapidly endocytosed.
Partial transcytosis of HAI-1 from the basolateral to the apical plasma membrane
To account for the very large concentration of HAI-1 in complex with matriptase that has been purified from milk [7] , it may be suggested that the basolateral pool of HAI-1 is transcytosed from the basolateral to the apical plasma membrane and released. To assess directly whether newly synthesized HAI-1 that appears on the basolateral membrane is routed to the apical plasma membrane, we used the following protocol: tight clone 21 cells grown on filters were pulse-labelled with [ 35 S]methionine for 90 min to ensure maximal labelling of HAI-1 molecules at the basolateral plasma membrane. The cells were then biotinylated on the basolateral surface with the cleavable reagent s-NHS-SSbiotin at 4
• C, followed by a second chase for 0 h or 4 h in order to allow transcytosis to occur. At the indicated times, the cells were either reduced twice with glutathione from the apical side or from the basolateral side, or reduction was omitted. This experiment demonstrated that HAI-1, biotinylated from the basolateral side after 4 h of chase at 37
• C, could be reduced from the apical side, indicating that a significant fraction of the HAI-1 molecules biotinylated on the basolateral plasma membrane was transcytosed to the apical plasma membrane (Figure 6 ). In addition, a significant fraction of HAI-1 molecules could be reduced from the basolateral side after 4 h of chase. This suggests that HAI-1 recycles between endosomes and the basolateral plasma membrane as the endocytosis rate is substantial (see Figure 5) . A control experiment showed that, without a second chase, the biotin could be reduced from the basolateral side, but not from the apical side.
Membrane-bound HAI-1 is eventually degraded in the lysosomes
To investigate whether HAI-1 is degraded in lysosomes we applied bafilomycin. Bafilomycin is a microbial toxin that reduces delivery of internalized proteins in multivesicular endosomes to the late endosomes/lysosomes [25] . Cells were grown on coverslips and pre-treated with 200 mM bafilomycin for 24 h or bafilomycin treatment was omitted. Cells were then fixed and stained to visualize HAI-1 surface and HAI-1 total as described previously. Confocal microscopy of the bafilomycin-treated cells showed that the major part of HAI-1 total was co-localized with HAI-1 surface (Figure 7 ). However, a substantial fraction of HAI-1 total does not co-localize with HAI-1 surface and represents intracellular HAI-1. This intracellular HAI-1 is not present in non-treated cells and demonstrates that HAI-1 is indeed accumulating in an intracellular compartment upon bafilomycin treatment, indicating that membrane-bound HAI-1 is eventually degraded in the lysosomes. We also tested whether HAI-1 co-localized with the lysosomal enzyme cathepsin D. However, no co-localization could be detected (results not shown) probably due to a low steadystate concentration of HAI-1 in the lysosomes.
DISCUSSION
In the present study we have mapped the subcellular itinerary of recombinantly expressed murine HAI-1 in the canine MDCK cell line. HAI-1 is expressed in vivo in many types of polarized epithelial cells and is near-ubiquitously co-expressed with the protease matriptase [3, 10, 26] . We have demonstrated that MDCK cells have an endogenous expression of both canine HAI-1 and canine matriptase, showing that MDCK cells are a relevant cell line for the study of the subcellular itinerary of these proteins. In the present study we have recombinantly expressed both murine HAI-1 and murine matriptase and studied their subcellular localization using antibodies not recognizing the endogenously expressed canine proteins, thereby proving the identity of the studied proteins. At steady-state, HAI-1 was found mainly on the basolateral plasma membrane in MDCK cells. This may seem contradictory to the fact that HAI-1 in complex with matriptase has been purified from milk [7] . We therefore investigated the subcellular localization of HAI-1 in mouse mammary gland epithelial cells during lactation and found that HAI-1 could be detected on the basolateral plasma membrane, again suggesting that the MDCK cells are a physiologically relevant model for studies of HAI-1 trafficking in polarized epithelial cells in vivo. Previous studies have shown that HAI-1 is located mainly on the basolateral plasma membrane in kidney cells [27] and a range of other polarized epithelial cells [6, 10, 27] .
The major part of the newly synthesized HAI-1 is exocytosed to the basolateral plasma membrane (Figure 8 , arrow A) from which it is rapidly endocytosed (Figure 8, arrow C) . From the basolateral plasma membrane there was a rapid endocytosis of approx. 75 % of the total cell-surface HAI-1 every 10 min. However, the transcytosis studies showed that after 4 h of chase approx. 30 % of HAI-1 was still reducible from the basolateral side. This suggests that HAI-1 recycles between the basolateral plasma membrane and endosomes for hours (Figure 8, arrow D) , which gives an explanation for the large pool of HAI-1 present at the basolateral membrane despite the rapid endocytosis rate. There are many examples of proteins recycling in a similar manner [28] .
Approx. 15 % of HAI-1 in MDCK cells is proteolytically released into the basolateral medium. This fraction is composed of a 45 kDa and a 40 kDa fragment. Proteolytic release of HAI-1 fragments has previously been reported from non-polarized cells [8, 27, 29] . There are at present no data to indicate whether a similar release of HAI-1 from the basolateral plasma membrane takes place in vivo. It is noteworthy that only a fraction of the HAI-1 molecules present on the basolateral membrane seem to be released. The degree of proteolytic release of membrane-bound proteins has previously been shown to depend on the degree of glycosylation. This is true for both N-glycosylation [30] and Oglycosylation [31, 32] . Human HAI-1 has been reported to contain three N-glycosylation sites [33] . Murine HAI-1 contains only one potential N-glycosylation site and one potential O-glycosylation consensus site at Thr 438 of the murine HAI-1, as analysed by the NetOGlyc 3.1 server [34] . To our knowledge there are no data regarding whether release of HAI-1 is dependent on glycosylation.
Despite a low steady-state pool of HAI-1 at the apical plasma membrane, our results suggest that HAI-1 does pass through this subcellular compartment during its cellular itinerary, made evident by the fact that significant amounts of HAI-1 are transcytosed from the basolateral to the apical plasma membrane (Figure 8 , arrows C and E). However, it is also possible that minor amounts of HAI-1 are exocytosed directly to the apical plasma membrane (Figure 8, arrow B) , not bypassing the basolateral plasma membrane.
Tight filter-grown MDCK cells are not absolutely tight, but soluble protein leaks through the filter, in the order of 5 % during 6 h [35] . The results of the present study showed that only a minor part of the HAI-1 was proteolytically released. The proteolytically released HAI-1 is distributed between the apical and the basolateral media as 11 % and 89 % respectively. Thus the fraction of the soluble HAI-1 released into the apical medium most probably represents molecules proteolytically released from the apical membrane as opposed to non-specific leakage though the monolayer of cells. Milk has been reported to be a rich source of HAI-1 in complex with matriptase [7] . To account for the large amount found in milk it is possible that the apical plasma membrane of mammary epithelial cells harbours proteases that release a larger fraction of the HAI-1 molecules or alternatively that the biosynthesis is so large that even a release comprising one-tenth of the biosynthesis is enough to generate the high concentration of proteolytically released HAI-1 found in milk.
In the present study we demonstrate that HAI-1 accumulates intracellularly upon treatment with bafilomycin, an inhibitor of transport to the lysosomes [36] , suggesting that membrane-bound HAI-1 is degraded in the lysosomes. We were unable to show co-localization of HAI-1 with the lysosomal protease cathepsin D, but this may merely reflect that the steady-state level of HAI-1 in the lysosomes is low due to a rapid turnover. We have not determined from which cellular compartment HAI-1 is directed to the lysosomes, but it is most probable that HAI-1 from the apical plasma membrane is directed to the lysosomes (Figure 8 , arrow F), as this would account for the low steady-state level of HAI-1 on the apical plasma membrane. HAI-1 from the Golgi apparatus is transported mainly to the basolateral plasma membrane (arrow A) but we cannot rule out that a minor fraction is transported directly to the apical plasma membrane (arrow B). HAI-1 is endocytosed from the basolateral plasma membrane (arrow C) and at least partly recycled back to the basolateral plasma membrane (arrow D). A substantial fraction of the HAI-1 molecules at the basolateral plasma membrane is transcytosed to the apical plasma membrane (arrow E). From both the apical and the basolateral plasma membrane there is a partial proteolytic release of the HAI-1 ectodomain symbolized by a pair of scissors. A fraction of the HAI-1 molecules is eventually degraded in the lysosomes. It was not determined from which cellular compartment HAI-1 is directed to the lysosomes, but it is most probably derived from the apical plasma membrane (arrow F), as this would account for the low steady-state concentration of HAI-1 found in this compartment.
In addition to a role in matriptase inhibition, HAI-1 is proposed to play a role in the activation and trafficking of matriptase [37, 38] . Thus, in the absence of HAI-1, matriptase is found to accumulate in the Golgi apparatus [38] . Matriptase activates prostasin via a proteolytic cleavage and they probably constitute the first two members of a proteolytic cascade regulating terminal differentiation [14] . Prostasin is located on the apical plasma membrane [40] , whereas matriptase is located on the basolateral membrane [41] . This leaves a spatial gap for the activation of prostasin by matriptase and potentially gives HAI-1 an important role in mediating the transport of matriptase from the basolateral membrane to the apical membrane via complex formation from where matriptase would be able to proteolytically activate prostasin. The MDCK cells recombinantly expressing HAI-1 and/or matriptase represent a model where it would be possible to obtain a better understanding of the subcellular sites of interaction between HAI-1 and matriptase and between matriptase and prostasin, which could give a better understanding of their role under normal physiological conditions as well as under pathological conditions, such as cancer.
